A Phase I Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 using the Intra-patient Escalation Dosing Regimen in Patients with Advanced Uveal Melanoma

Protocol: 
AAAQ4601
Phase: 
I

A Phase I Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 using the Intra-patient Escalation Dosing Regimen in Patients with Advanced Uveal Melanoma

This is a Phase I study of a weekly intra-patient escalation dose regimen with IMCgp100 in patients with metastatic uveal melanoma (mUM). To help decide whether or not patients can take part in a research study looking at a new form of treatment for advanced uveal melanoma, their blood need to first be tested to determine their Human Leukocyte Antigen (HLA) type. To be able to take part in the research study, patients need to be HLA type A2 positive. The sponsor believes that this type of cancer is more likely to respond to this new type of treatment if they are also HLA type A2 positive. The study doctor does not know the patients' HLA type so he/she will need to do a blood test to find out. About half of the general population are HLA type A2 positive.

Are you Eligible? (Inclusion Criteria)

1. Patients must have metastatic uveal melanoma
2. Patients must be HLA-A2 positive
3. Patients must have adequate bone marrow and organ function
4. Patients must have recovered from all side effects associated with prior therapy

Specialty Area(s)

Immunotherapy

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States